PF-Atlas › Clinical Trials › NCT00097773
Comparison of Two Treatment Regimens to Reduce PA Infection in Children With Cystic Fibrosis
Tobramycin solution for inhalation · Phase 2
Registry ID
NCT00097773
Phase
Phase 2
Status
Completed
Drug / intervention
Tobramycin solution for inhalation (TOBI)
Sponsor
Seattle Children's Hospital
Start
2004-09
Enrollment
304
Locations
54
About this trial
Cystic fibrosis (CF) is a chronic disease that significantly affects an individual's lung function. Antibiotic medications have been proven effective at reducing Pseudomonas aeruginosa (PA) infection, which is one of the main causes of death in individuals with CF. The purpose of this study is to compare the effectiveness of treatment based on quarterly culture results versus consistent quarterly antibiotic treatment at reducing PA infection in children with CF.
Explore related
Related trials
Medical disclaimer. This page summarizes public trial data for NCT00097773 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.